Navigation Links
United Therapeutics Corporation Reports Third Quarter 2011 Financial Results
Date:10/27/2011

sic common share

$

1.45$

0.70$

3.01$

1.73DilutedContinuing operations

$

1.32$

0.67$

2.80$

1.63Discontinued operations

$

0.06$

(0.01)$

0.01$

(0.01)Net income per diluted common share

$

1.38$

0.66$

2.81$

1.62Weighted average number of common shares outstanding:Basic

58,32156,53658,08755,790Diluted

61,21060,21662,06259,545SELECTED CONSOLIDATED BALANCE SHEET DATASeptember 30, 2011(Unaudited, in thousands)Cash, cash equivalents and marketable securities (excluding restricted amounts of $5.1 million)

$

944,593Total assets

1,667,053Total liabilities and common stock subject to repurchase

582,084Total stockholders' equity

1,084,969
'/>"/>

SOURCE United Therapeutics Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. United States Holds Global Lead in Breast Cancer Research Publications as China Surges to Forefront, According to Report
2. United Therapeutics Corporation to Announce Third Quarter 2011 Financial Results Before Market Open on Thursday, October 27, 2011
3. United Therapeutics Announces Proposed Private Offering of $210 Million of Convertible Senior Notes and Authorization of Stock Repurchase Program
4. United Therapeutics Subsidiary Enters Into Contract With National Institutes of Health for Award of up to $45 Million to Support Glycobiology Antiviral Program
5. Full-day "United Nations" Online Investor Conference: October 6th at RetailInvestorConferences.com
6. United Therapeutics Corporation Reports Second Quarter 2011 Financial Results
7. FDA Advisory Panel Unanimously Recommends Approval of EXCOR(R) Pediatric Ventricular Assist Device for Use in the United States
8. Daiichi Sankyo Selects Veeva CRM to Support Customer Engagement Initiatives in the United Kingdom
9. United Therapeutics Corporation To Announce Second Quarter 2011 Financial Results Before Market Open on Thursday, July 28, 2011
10. United Therapeutics Corporation Completes Enrollment of FREEDOM-C(2) Trial
11. United Therapeutics Corporation Reports 2010 Fourth Quarter and Annual Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/1/2014)... N.J., Aug. 1, 2014 Cambrex Corporation (NYSE: ... June 30, 2014. Highlights , ... million in the same period last year. , Second ... million in the same period last year (see table at ... sales guidance increased, excluding the impact of foreign currency, to ...
(Date:7/31/2014)... (PRWEB) July 31, 2014 Food ... are increasingly searching for food alternatives that offer ... benefits. The food ingredient market has numerous players ... such as Vital Force Technology (VFT). VFT ... than 4,000 energetic patterns, all tested to produce ...
(Date:7/31/2014)... , July 31, 2014 Nearly 20,000 medical ... Annual Meeting & Clinical Lab Expo in ... featured never-before-seen breakthroughs in diagnostic research and technology that ... need. As of Wednesday, July 30, more ... Annual Meeting & Clinical Lab Expo, with more than ...
(Date:7/31/2014)... to see through organs and even the entire body ... fine-grained cellular structures has been a long-time dream of ... July 31st in the journal Cell has ... for making opaque organs, bodies, and human tissue biopsies ... The protocols could pave the way for a better ...
Breaking Biology Technology:Cambrex Reports Second Quarter 2014 Financial Results 2Cambrex Reports Second Quarter 2014 Financial Results 3Cambrex Reports Second Quarter 2014 Financial Results 4Cambrex Reports Second Quarter 2014 Financial Results 5Cambrex Reports Second Quarter 2014 Financial Results 6Cambrex Reports Second Quarter 2014 Financial Results 7Cambrex Reports Second Quarter 2014 Financial Results 8Cambrex Reports Second Quarter 2014 Financial Results 9Cambrex Reports Second Quarter 2014 Financial Results 10Cambrex Reports Second Quarter 2014 Financial Results 11Cambrex Reports Second Quarter 2014 Financial Results 12Cambrex Reports Second Quarter 2014 Financial Results 13Cambrex Reports Second Quarter 2014 Financial Results 14Cambrex Reports Second Quarter 2014 Financial Results 15Cambrex Reports Second Quarter 2014 Financial Results 16Functional Ingredient Manufacturer – Vital Force Technology Infuses Raw Materials & Ingredients with Subtle Energy Formula 2Research on Digital Health, Alzheimer's, Ebola Draws Nearly 20,000 Attendees to 2014 AACC Annual Meeting & Clinical Lab Expo 2Research on Digital Health, Alzheimer's, Ebola Draws Nearly 20,000 Attendees to 2014 AACC Annual Meeting & Clinical Lab Expo 3See-through organs and bodies will accelerate biomedical discoveries 2
... , Multiporator , , , , , , , ... Protocol No. 4308 915.032 03/2000 , , , ... , , Cell line , ... Transfection with , Plasmid pEGFP-N1 (in bidistilled H 2 O), ...
... , , , , Multiporator / Electroporator 2510 , , , ... Transformation Protocol , Protocol No. 4308 915.508 12/2001 , ... , , , , ... , Cell type , Bacteria, gram ...
... Multiporator / Electroporator 2510 , , , , , , , ... Protocol No. 4308 915.538 04/2002 , , , ... , , Microorganism , ... Cell type , Bacteria, gram positive, , ...
Cached Biology Technology:BW 5147 2Brucella abortus 2Bifidobacterium animalis 2
(Date:7/31/2014)... the National Science Foundation (NSF), counters a widely-held ... warming, indicating instead that certain Arctic lakes store ... atmosphere. , The study, published this week ... thermokarst lakes, which occur as permafrost thaws and ... water, converting what was previously frozen land into ...
(Date:7/31/2014)... study (HPV-023; NCT00518336) shows the sustained efficacy, ... virus (HPV) vaccine Cervarix. Women vaccinated with ... more than nine years, and vaccine efficacy ... is the longest follow-up report for a ... for the full paper. , HPV ...
(Date:7/31/2014)... 100 percent of animal models against the highly infectious ... an intestinal disease that kills approximately 30,000 Americans annually. ... Infection and Immunity . , In the study, ... the purified toxins produced by C. difficile , ... laboratory model that mimics the human disease, after only ...
Breaking Biology News(10 mins):Certain Arctic lakes store more greenhouse gases than they release 2Sustained efficacy, immunogenicity, and safety for GlaxoSmithKline's HPV vaccine 2Sustained efficacy, immunogenicity, and safety for GlaxoSmithKline's HPV vaccine 3C. difficile vaccine proves safe, 100 percent effective in animal models 2
... release is available in German . , ... - a North African bird species with a very ... from attractive males of the same species positively affects ... highly displaying male birds in the experiment were more ...
... Institute of Standards and Technology (NIST) scientists have moved a ... blood test that can scan for thousands of disease markers ... has learned how to decode the electrical signals generated by ... artificial cell membrane. Nanopores are not new themselves; for ...
... of atherosclerosis has allowed researchers to identify a host of ... the process, before a plaque appears in the affected blood ... Blood, the journal of the American Society of Hematology. ... disturbances in the patterns of blood flow in an artery ...
Cached Biology News:Pleasing to the eye 2Pleasing to the eye 3NIST team advances in translating language of nanopores 2To predict atherosclerosis, follow the disturbed blood flow 2
Chicken polyclonal to DCTD ( Abpromise for all tested applications). Antigen: Full length protein (Human) Entrez GeneID: 1635 Swiss Protein ID: P32321...
Mouse monoclonal [SPM325] to Xanthine Oxidase, prediluted ( Abpromise for all tested applications). Antigen: C terminal 358 amino acid fragment of human xanthine oxidase. Entrez Gene ID: 749...
Mouse monoclonal [2G1] to Vancomycin ( Abpromise for all tested applications)....
Phospho- (Ser) 14-3-3 Binding Motif (4E2) Mouse mAb...
Biology Products: